

pTK-GLuc Vector



1-800-632-7799
info@neb.com
www.neb.com



N8084S 004120715071

N8084S

20 µg Lot: 0041207 Exp: 7/15

0.5 µg/µl Store at -20°C

Description: The pTK-GLuc Vector contains the coding sequence for the secreted *Gaussia* luciferase (GLuc) under the control of the Herpes Simplex Virus (HSV) thymidine kinase (TK) promoter, for constitutive expression in mammalian cells. It contains multiple cloning sites after the GLuc open reading frame (i.e. in the 3' untranslated region) that can be used to insert heterologous sequences. Such constructs can be used for RNA studies including RNA stability, siRNA potency/efficacy, etc. by measuring the GLuc activity (1).


Gaussia luciferase is a new reporter luciferase from the marine copepod *Gaussia princeps* (2,3). This luciferase, which does not require ATP, catalyzes the oxidation of the substrate coelenterazine in a reaction that emits light (470 nm).

Source: Isolated from *E. coli* strain NEB 10-beta by a standard DNA purification procedure.

Supplied in: 10 mM Tris-HCl (pH 7.5 @ 25°C), 1 mM EDTA.

Advantages:

- GLuc possesses a natural secretory signal and upon expression is secreted into the growth medium. Therefore, **lysis of the cells is not necessary** before assaying the activity. This allows for multiple samples to be assayed at different time points from the same transfected cells.
- GLuc generates over 1000-fold higher bioluminescent signal intensity than Firefly and *Renilla* luciferases, making it an ideal sensitive transcriptional reporter (3).
- The secreted GLuc is very stable and can be stored for several days at 4°C without loss of activity.



Restriction map of pTK-GLuc Vector. Only unique restriction sites are shown. The complete sequence and restriction map is available at: http://www.neb.com/nebecomm/tech_reference/ (see other side)

CERTIFICATE OF ANALYSIS

pTK-GLuc Vector



1-800-632-7799
info@neb.com
www.neb.com



N8084S 004120715071

N8084S

20 µg Lot: 0041207 Exp: 7/15

0.5 µg/µl Store at -20°C

Description: The pTK-GLuc Vector contains the coding sequence for the secreted *Gaussia* luciferase (GLuc) under the control of the Herpes Simplex Virus (HSV) thymidine kinase (TK) promoter, for constitutive expression in mammalian cells. It contains multiple cloning sites after the GLuc open reading frame (i.e. in the 3' untranslated region) that can be used to insert heterologous sequences. Such constructs can be used for RNA studies including RNA stability, siRNA potency/efficacy, etc. by measuring the GLuc activity (1).


Gaussia luciferase is a new reporter luciferase from the marine copepod *Gaussia princeps* (2,3). This luciferase, which does not require ATP, catalyzes the oxidation of the substrate coelenterazine in a reaction that emits light (470 nm).

Source: Isolated from *E. coli* strain NEB 10-beta by a standard DNA purification procedure.

Supplied in: 10 mM Tris-HCl (pH 7.5 @ 25°C), 1 mM EDTA.

Advantages:

- GLuc possesses a natural secretory signal and upon expression is secreted into the growth medium. Therefore, **lysis of the cells is not necessary** before assaying the activity. This allows for multiple samples to be assayed at different time points from the same transfected cells.
- GLuc generates over 1000-fold higher bioluminescent signal intensity than Firefly and *Renilla* luciferases, making it an ideal sensitive transcriptional reporter (3).
- The secreted GLuc is very stable and can be stored for several days at 4°C without loss of activity.



Restriction map of pTK-GLuc Vector. Only unique restriction sites are shown. The complete sequence and restriction map is available at: http://www.neb.com/nebecomm/tech_reference/ (see other side)

CERTIFICATE OF ANALYSIS

pTK-GLuc Vector MCS

NotI AgeI XhoI XbaI
GGGCCGGTGCTGACTAAGCGGCCGCACCGGTCTCGAGCATGCATCTAGA
...A G G D *

GLuc

pTK-GLuc multiple cloning site (MCS). The Gaussia Luciferase sequence is shown with a blue background. Only unique restriction sites are shown.

Features of pTK-GLuc Vector:

- Constitutive expression of secreted GLuc
- MCS at the 3' untranslated region of GLuc
- Neomycin resistance

pTK-GLuc Vector MCS

NotI AgeI XhoI XbaI
GGGCCGGTGCTGACTAAGCGGCCGCACCGGTCTCGAGCATGCATCTAGA
...A G G D *

GLuc

pTK-GLuc multiple cloning site (MCS). The Gaussia Luciferase sequence is shown with a blue background. Only unique restriction sites are shown.

Features of pTK-GLuc Vector:

- Constitutive expression of secreted GLuc
- MCS at the 3' untranslated region of GLuc
- Neomycin resistance

References:

1. Morlighem, J.E., Petit, C. and Tzertzinis, G. (2007) *Biotechniques* 42, 599–614.
2. Verhaegen, M. and Christopoulos, T.K. (2002) *Anal. Chem.* 74,4378–4385.
3. Tannous, B.A., Kim, D.E., Fernandez, J.L., Weissleder, R., and Breakefield, X.O. (2005) *Mol. Ther.* 11, 435–443.

Companion Products Sold Separately:

Gaussia Luciferase Assay Kit
#E3300S 100 assays
#E3300L 1,000 assays

pGLuc-Basic Vector
#N8082S 20 µg

pCMV-GLuc Control Plasmid
#N8081S 20 µg

TransPass™ D2 Transfection Reagent
#M2554S 0.6 ml
#M2554L 3.0 ml

References:

1. Morlighem, J.E., Petit, C. and Tzertzinis, G. (2007) *Biotechniques* 42, 599–614.
2. Verhaegen, M. and Christopoulos, T.K. (2002) *Anal. Chem.* 74,4378–4385.
3. Tannous, B.A., Kim, D.E., Fernandez, J.L., Weissleder, R., and Breakefield, X.O. (2005) *Mol. Ther.* 11, 435–443.

Companion Products Sold Separately:

Gaussia Luciferase Assay Kit
#E3300S 100 assays
#E3300L 1,000 assays

pGLuc-Basic Vector
#N8082S 20 µg

pCMV-GLuc Control Plasmid
#N8081S 20 µg

TransPass™ D2 Transfection Reagent
#M2554S 0.6 ml
#M2554L 3.0 ml

LICENSE/PATENTS/DISCLAIMERS:

Recipient is legally bound and accepts the following terms and conditions:

Non-Commercial Entities: This product is covered by US Patent 6,232,107 and other patents that are legal property as assigned to Prolume Ltd./Nanolight Technologies. This product is licensed only to the purchasing laboratory-research group. Recipient agrees not to transfer this plasmid or derivatives of this vector to any other laboratory, person or research group, even if within the same institution.

Recipient agrees not to alter or make any changes to the nucleotide coding sequence or secretory coding sequence of the luciferase(s) contained within without prior written permission from Prolume Ltd./Nanolight Technologies (www.nanolight.com). Recipient agrees not to file for any patent rights or to any inventions claiming any portion of the luciferase(s) within this material without prior written permission from Prolume Ltd./Nanolight Technologies.

Commercial For-Profit Entities & Non-Profit Foundations (herein referred to as Commercial Recipients): Commercial Recipients wishing to derive products, engage in the sale or license of any products, discover drugs or make inventions by use of the materials enclosed, fully agree to the terms mentioned above for Non-Commercial Entities; AND ADDITIONALLY agree to and are hereby bound to use the materials FOR EVALUATION PURPOSES ONLY. Commercial Recipient hereby agrees to destroy and cease use of any materials or derivatives containing any portion of these materials within 120 days from receipt. Commercial Recipient agrees not to use the materials for any use, other than the 120 day suitability evaluation without prior written permission or obtaining a valid license from Prolume Ltd./Nanolight Technologies.

Any recipient that does not accept the license terms mentioned above, shall return the unopened package and materials to NEB for a full refund.

LICENSE/PATENTS/DISCLAIMERS:

Recipient is legally bound and accepts the following terms and conditions:

Non-Commercial Entities: This product is covered by US Patent 6,232,107 and other patents that are legal property as assigned to Prolume Ltd./Nanolight Technologies. This product is licensed only to the purchasing laboratory-research group. Recipient agrees not to transfer this plasmid or derivatives of this vector to any other laboratory, person or research group, even if within the same institution.

Recipient agrees not to alter or make any changes to the nucleotide coding sequence or secretory coding sequence of the luciferase(s) contained within without prior written permission from Prolume Ltd./Nanolight Technologies (www.nanolight.com). Recipient agrees not to file for any patent rights or to any inventions claiming any portion of the luciferase(s) within this material without prior written permission from Prolume Ltd./Nanolight Technologies.

Commercial For-Profit Entities & Non-Profit Foundations (herein referred to as Commercial Recipients): Commercial Recipients wishing to derive products, engage in the sale or license of any products, discover drugs or make inventions by use of the materials enclosed, fully agree to the terms mentioned above for Non-Commercial Entities; AND ADDITIONALLY agree to and are hereby bound to use the materials FOR EVALUATION PURPOSES ONLY. Commercial Recipient hereby agrees to destroy and cease use of any materials or derivatives containing any portion of these materials within 120 days from receipt. Commercial Recipient agrees not to use the materials for any use, other than the 120 day suitability evaluation without prior written permission or obtaining a valid license from Prolume Ltd./Nanolight Technologies.

Any recipient that does not accept the license terms mentioned above, shall return the unopened package and materials to NEB for a full refund.